Heart drug camzyos may do more than clear Blockages—New study investigates
NCT ID NCT07120776
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the heart medication Camzyos (Mavacamten) can improve blood flow to the heart muscle in people with hypertrophic obstructive cardiomyopathy (HOCM). Researchers will use special PET-CT scans to measure blood flow before and after 12 months of treatment. Up to 75 adults with HOCM who are already starting Camzyos as part of their routine care will take part. The goal is to see if the drug helps reduce chest pain and shortness of breath by improving oxygen supply to the heart.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Camzyos (Mavacamten)
- What this could lead to
- If successful, this could show that Camzyos not only relieves obstruction but also improves blood supply to the heart, potentially guiding better treatment for HOCM.
- What could go wrong
- This is a small, early-stage observational study (75 people) that does not test the drug itself—it only observes effects. Results may not apply to all patients, and the drug's known side effects include heart-related risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY \(HOCM\) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Manchester University NHS Foundation Trust
RECRUITINGManchester, M13 9WL, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.